Tirzepatide is a once-weekly, prescription injectable for chronic weight management. Originally developed for type 2 diabetes, it targets two incretin receptors – GIP and GLP-1 – to regulate appetite, slow gastric emptying, and stabilize blood sugar. In eligible adults with obesity or those who are overweight with related health risks, this dual action can reduce hunger, enhance satiety, and support significant, sustained weight loss as part of a medically supervised program.